UNSPSC 51333407: Mafoprazine

This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D7UUO54C6N. European Medicines Agency schedules Mafoprazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08634MIG. Mafoprazine generally arises in the molecular formula C22H28FN3O3.

UNSPSC 51333407 Mafoprazine is a Commodity code representing pharmaceutical products procured by state and local health and emergency-response agencies. The code sees little recent state and local activity aligned with its nominal scope; the single recent opportunity shows a mismatch between the code tag and the actual procurement. Seminole County, Florida posted an IFB (Solicitation Number IFB60459723LAS) for Naloxone and Safe Drug Deactivation Systems—opioid-reversal and drug-disposal products—rather than mafoprazine, a psychiatric medication. The county's procurement reflects community health and harm-reduction priorities, with quarterly deliveries of 1,900 units of Naloxone and 800 deactivation systems annually to the Seminole County Community Health Building in Sanford, Florida. Vendors must include all shipping and delivery costs, hold appropriate insurance coverage (workers' compensation, commercial general liability, professional liability), and comply with E-Verify and drug-free workplace certifications. The contract structure includes a two-year initial term with a one-year renewal option and a three-month probationary period allowing termination at will.

The opportunity was posted June 30, 2026, with a response deadline of July 26, 2023—a date inconsistency in the source suggesting data quality issues in the underlying record. Geographic activity is limited to Florida, with Seminole County as the sole identified recent buyer. Potential FEMA funding introduces federal compliance requirements including the Clean Air Act and Federal Water Pollution Control Act, along with audit and record-inspection exposure. No explicit set-asides for disadvantaged enterprises are noted. The code shows minimal recent procurement velocity aligned with its stated scope; firms evaluating activity under this code should verify whether the mismatch reflects persistent tagging errors or actual demand for mafoprazine by state and local buyers.